{"filings":[{"id":94306,"accession_number":"0001639691-26-000031","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.","Raised FY2026 constant-currency revenue growth guidance to 7.0%-8.0% (up 100bps); adjusted EPS guidance raised to $4.20-$4.30.","Received FDA PMA for aura6000 HGNS system for moderate-to-severe OSA; no CCC contraindication or pre-implant DISE required.","Published 12-month OSPREY trial results in Annals of Internal Medicine; demonstrated clinically significant responses.","Q1 adjusted free cash flow $3.8M; maintained FY2026 adjusted FCF guidance $160M-$180M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":362258000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106564,"accession_number":"0001639691-26-000006","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.","Full-year GAAP diluted loss per share $4.45 includes $365.6M SNIA environmental charge.","Full-year adjusted diluted EPS $3.90; adjusted free cash flow $183.3M.","2026 guidance: constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25.","CMS increased reimbursement for VNS Therapy DRE procedures effective Jan 1, 2026; FDA approved cloud-based digital health platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1388053000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106563,"accession_number":"0001639691-26-000002","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LivaNova SVP, Chief Legal Officer Michael Hutchinson resigns effective Jan 26, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Hutchinson notified resignation on Jan 12, 2026 as SVP, Chief Legal Officer, and Company Secretary.","Resignation to pursue another opportunity; last day with LivaNova is January 26, 2026.","Company plans to retain external search firm to find a new Chief Legal Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122899,"accession_number":"0001639691-25-000146","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.","GAAP diluted EPS $0.49; adjusted diluted EPS $1.11.","Raised FY2025 guidance: revenue growth 8.5%-9.5% constant currency, EPS $3.80-$3.90, FCF $160M-$180M.","Initiated commercial launch of Essenz Perfusion System in China, the second-largest heart-lung machine market.","Appointed Donald Zurbay to the Board of Directors and Audit and Compliance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1027132000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139598,"accession_number":"0001639691-25-000120","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints Donald Zurbay to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald Zurbay appointed to LivaNova Board and Audit & Compliance Committee effective September 4, 2025.","Zurbay most recently President & CEO of Patterson Companies (Oct 2022-May 2025); previously CFO at Patterson and St. Jude Medical.","Compensation: $70k annual retainer, $15k audit committee fee, $185k annual restricted stock award, prorated until 2026 AGM.","No material transactions or arrangements between Zurbay and LivaNova per Item 404(a) review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139597,"accession_number":"0001639691-25-000099","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.","Raised FY25 guidance: revenue growth 8-9% constant-currency, adj. EPS $3.70-$3.80 (midpoint +$0.10).","Adj. free cash flow $47.8M; FY25 raised to $140-160M.","Initiated CMS reconsideration for VNS Therapy for treatment-resistant depression based on RECOVER study.","Published 24-month CORE-VNS data showing VNS reduces generalized tonic-clonic seizures in DRE."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":669379000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157180,"accession_number":"0001639691-25-000052","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LivaNova shareholders approve 2.2M share increase in 2022 incentive plan and new director plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Second Amended & Restated 2022 Incentive Award Plan, adding 2,200,000 shares for awards.","Also approved 2025 Director Incentive Award Plan, making 300,000 shares available for non-executive director equity compensation.","All 12 proposals passed, including director elections and advisory votes on executive compensation.","The 2025 Director Plan is successor to the 2015 Plan; no further awards under 2015 Plan.","Votes: ~93% approval for both plans; approximately 83.59% of shares represented at AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157179,"accession_number":"0001639691-25-000047","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Italian Ministry seeks €108.8M minimum costs in SNIA case; LivaNova disputes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On May 15, 2025, Italian Ministry served filing to Court of Appeal seeking minimum costs of approximately €108.8M, contrary to Supreme Court's decision that disapproved €157.3M.","LivaNova recorded €333.3M ($360.4M) current liability as best estimate for the SNIA environmental matter as of March 31, 2025.","Company disagrees with Ministry's assertions and intends to challenge them; no change to full-year 2025 guidance.","Italian Supreme Court referred case back to Court of Appeal for implementation regarding costs and damages per its judgment.","Ministry also requested a hearing in 2026 in connection with the proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157178,"accession_number":"0001639691-25-000038","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q1: rev $316.9M (+10.4% organic); GAAP EPS -$6.01 (SNIA charge); adj EPS $0.88; FY25 adj EPS guide $3.60-$3.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $316.9M, +7.4% reported, +10.4% organic vs Q1 2024.","GAAP diluted loss per share $6.01 from €333.3M SNIA environmental liability ($360.4M).","Adjusted diluted EPS $0.88; adjusted free cash flow $20.0M.","FY25 constant-currency revenue growth guidance raised to 6-7%; organic 7-8%; adj EPS $3.60-$3.70.","Completed PMA submission for aura6000 System; OSPREY 12-month data showed strong response."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":316855000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175526,"accession_number":"0001639691-25-000014","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"LivaNova to record ~€333M liability after Italian Supreme Court ruling on SNIA environmental case","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Italian Supreme Court rules LivaNova jointly liable for SNIA environmental liabilities of €454M, but excludes €157M in prior payments.","Company expects to record a liability of ~€333M ($363M) in Q1 2025 as best estimate including costs, fees, interest, and taxes.","LivaNova has sufficient resources: cash $429M and restricted cash $295M as of Dec 31, 2024 to cover the liability.","Case remanded to Court of Appeal of Milan to implement decision on costs and damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175525,"accession_number":"0001639691-25-000008","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.","FY2024 revenue $1.25B (+10.7% organic); GAAP EPS $1.16, adjusted EPS $3.38.","FY2025 guidance: constant-currency revenue growth 5-6%, adjusted EPS $3.65-$3.75, adjusted FCF $135-155M.","OSPREY sleep apnea study met primary safety and efficacy endpoints at 6 months; RECOVER depression study publications support VNS Therapy.","Natalia Kozmina appointed Chief Human Resources Officer in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1253437000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192480,"accession_number":"0001639691-24-000139","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.","LivaNova says it is disappointed by the decision but does not expect any impact on its business.","The company plans to continue pursuing improved reimbursement for VNS Therapy for DRE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192479,"accession_number":"0001639691-24-000129","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q3 revenue $318.1M (+11.2% YoY); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $318.1M, up 11.2% reported and constant-currency; ex-ACS wind down, growth 12.3% constant-currency.","GAAP diluted EPS of $0.60; adjusted diluted EPS of $0.90.","Raised full-year 2024 guidance; company cites strong execution and momentum.","Board appointed Susan Podlogar in October 2024; serves on Compensation and Human Capital Management Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":931607000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192478,"accession_number":"0001639691-24-000125","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints Susan Podlogar to board and compensation committee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed October 8, 2024 to Board and Compensation and Human Capital Management Committee.","Podlogar, 61, served as MetLife EVP/CHRO until June 2024 and 16 years at Johnson & Johnson.","Receives $60,000 annual retainer, $8,000 committee fee, and $180,000 RSU grant prorated for 2024.","No material transactions or arrangements between Podlogar and LivaNova since Jan 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208952,"accession_number":"0001639691-24-000117","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LivaNova CHRO Trui Hebbelinck to depart Sept 30; search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trui Hebbelinck will leave as Chief Human Resources Officer on Sept 30, 2024, then on garden leave until Sept 30, 2025.","She receives normal salary/benefits during garden leave, no 2025 bonus; equity awards continue vesting per terms.","Settlement includes prorated 2024 bonus at on-target, £232k severance, outplacement up to £20k, and tax/legal assistance.","Company retained an external search firm to find a new Chief Human Resources Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208951,"accession_number":"0001639691-24-000105","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.","GAAP diluted EPS $0.30; adjusted diluted EPS $0.93.","Raised full-year 2024 revenue and adjusted diluted EPS guidance.","Franco Poletti named President of Cardiopulmonary Business Unit, effective August 1, 2024.","Plans to pursue CMS coverage for VNS Therapy in RECOVER patient population; reducing 2025 investment in difficult-to-treat depression."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":613487000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226772,"accession_number":"0001639691-24-000075","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LivaNova shareholders approve equity plan share pool increases at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["A&R 2022 Plan options/SARs pool increased to 2,950,000 shares from 2,250,000; other awards to 2,000,000 from 1,500,000.","2015 Plan non-employee director pool raised to 150,000 shares from 50,000; plan expiration extended to June 2034.","All nine director nominees re-elected; advisory say-on-pay approved with ~95% of votes cast in favor.","Advisory vote on say-on-pay frequency set to annual; 22.2M votes for 1-year vs 5.1M abstentions and 20.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226771,"accession_number":"0001639691-24-000054","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.","Cardiopulmonary and Neuromodulation each grew double-digit; ACS wind down on track for end-2024.","Raised full-year 2024 revenue and adjusted diluted EPS guidance (exact figures not in excerpt).","Positive predictive outcome in OSPREY obstructive sleep apnea study; enrollment completed.","Closed $345M 2.50% convertible notes due 2029; repurchased $230M exchangeable notes due 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":294912000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245736,"accession_number":"0001639691-24-000034","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"LivaNova issues $345M convertible notes, repurchases $230M of existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $345M aggregate principal of 2.50% convertible senior notes due 2029","Repurchased $230M of existing 3.00% Cash Exchangeable Senior Notes for ~$270.5M","Entered into capped call transactions covering shares underlying the notes","Amended credit agreement, increasing revolving facility from $125M to $225M"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245735,"accession_number":"0001639691-24-000031","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova prices $300M 2.5% convertible notes due 2029; plans to repurchase $230M of 3% exchangeable notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $300M aggregate principal of 2.50% convertible senior notes due 2029; initial purchasers may buy up to $45M more.","Net proceeds estimated at ~$289.3M ($333M if over-allotment exercised); use includes repurchasing $230M of existing 3% notes.","Initial conversion price $69.40/share, a 32.5% premium to LIVN's $52.38 close on March 5, 2024.","Entered capped call transactions with cap price $94.284/share to offset dilution upon conversion.","Plans to repurchase $230M of 3.00% Cash Exchangeable Senior Notes due 2025 for $270.5M cash (incl. interest)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245734,"accession_number":"0001639691-24-000027","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova announces $300M convertible note offering due 2029, with $45M greenshoe","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Proposed $300M convertible senior notes due 2029; initial purchasers granted 13-day option for additional $45M.","Notes are senior unsecured, convertible upon conditions; interest rate and conversion rate to be determined at pricing.","Enters capped call transactions to offset dilution; also considering repurchasing some of its 3.00% exchangeable notes due 2025.","Net proceeds to fund capped calls, repurchases, and general corporate purposes; also negotiating credit facility amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245733,"accession_number":"0001639691-24-000016","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue $310M (+12.8%), adj. EPS $0.87; full-year $1.15B; new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $310.1M, up 12.8% reported (11.9% constant currency) vs prior year.","Q4 GAAP diluted EPS $0.30; adjusted diluted EPS $0.87.","Full-year 2023 revenue $1.15B, up 12.9% reported (13.3% constant currency).","Full-year GAAP diluted EPS $0.32; adjusted diluted EPS $2.80, up 17% YoY.","Board named Vladimir A. Makatsaria CEO effective March 1, 2024; winding down Advanced Circulatory Support segment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1153545000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245732,"accession_number":"0001639691-24-000013","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LivaNova appoints Vladimir Makatsaria as CEO effective March 1, 2024; Kozy remains Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vladimir Makatsaria, former J&J MedTech Ethicon head, named CEO and Board member effective March 1, 2024.","Makatsaria receives annual base salary of $930,000, target bonus of 110% of base, and LTI grants totaling $6.85M.","Interim CEO William Kozy steps down as CEO on March 1 but continues as Board Chair.","Employment agreement includes sign-on cash bonus of $200,000 and relocation benefits from NYC to Houston.","Makatsaria holds BA in Physiology, MBA and MHA from University of Minnesota."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}